Clinical trials
Efficacy and Safety clinical trials
Below are recruiting efficacy and safety clinical trials, each written for real people, not researchers. We’re tracking 2,799 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07302581Recruiting
Study of dental implants with natural ligament for single tooth replacement
This trial tests a new type of dental implant that includes a ligament (like a natural tooth's shock absorber). It's for people who need to have a single front or side tooth pulled and have healthy gum and bone around the area. The goal is to see if this implant works well and stays healthy over time.
Kōriyama, FukushimaAges 18 years+ - NCT07303296RecruitingPhase 2
Gene therapy study for vision loss from LHON
This trial tests a gene therapy called GS010 given as an injection into the eye for people with vision loss from LHON. It aims to see if it can help improve vision in both eyes.
ParisAges 15 years+ - NCT07303387RecruitingPhase 2
Valemetostat for solid tumors with SWI/SNF gene changes
This trial tests a new drug, valemetostat, for solid tumors that have specific genetic changes (like loss of SMARCB1, SMARCA4, or ARID1A). It is for people whose cancer has continued to grow despite other treatments. The study will see if valemetostat can help shrink or slow tumors.
Villejuif, Val de MarneAges 18 years+ - NCT07307170Recruiting
Mirogabalin for shingles pain study
This trial tests a new pain medicine called mirogabalin for people with shingles pain that started within the last 30 days. It aims to see if the drug can safely reduce moderate to severe pain.
BeijingAges 18 years+ - NCT07307976Recruiting
Testing a new pain drug for shingles pain
This trial tests a new medicine called crisugabalin to see if it safely reduces shingles pain. It may help if you have moderate to severe pain from a shingles rash that started less than 3 months ago.
BeijingAges 18 years+ - NCT07313618RecruitingEarly Phase 1
Gene therapy for children with oculocutaneous albinism type 1
This trial tests a single injection of JWK010 gene therapy for children aged 5 to 12 with OCA1A albinism. The therapy is given into the eye to try to improve vision, and is meant for those who have not had gene therapy before.
Chengdu, SichuanAges 5–12 - NCT07315061RecruitingPhase 2
Testing D-2570 for active psoriatic arthritis
This trial tests an oral medication, D-2570, for people with active psoriatic arthritis. It aims to see if the drug can reduce joint pain and swelling.
Chengdu, SichuanAges 18–70 - NCT07319377Recruiting
Digital therapy to improve strength in muscle loss
This trial tests a digital device to help people with sarcopenia (age-related muscle loss) build strength through a guided exercise program on a mobile phone.
Bucheon-siAges 50–85 - NCT07320495Recruiting
Automated insulin delivery for type 1 diabetes
This trial tests a new automated insulin delivery system (APGO algorithm) to see how well it controls blood sugar and if it's safe. It may help people with type 1 diabetes manage their condition more easily.
PragueAges 18 years+ - NCT07321093RecruitingPhase 3
A study of BCD-281 for relapsing-remitting MS
This trial tests a new medicine called BCD-281 for people with relapsing-remitting multiple sclerosis (RRMS). It aims to see if the drug can reduce relapses and improve disease control.
Nizhny NovgorodAges 18–55 - NCT07322718RecruitingEarly Phase 1
Testing RXIM002 for severe autoimmune diseases
This study tests a new drug called RXIM002 for people with severe autoimmune diseases that haven't improved with standard treatments. It aims to see if targeting immune cells with the CD19 marker can help control the disease.
Shanghai, Huangpu DistrictAges 18–65 - NCT07324707RecruitingPhase 2
Asthma study testing PA9159 inhaled spray
This trial tests an inhaled asthma medication, PA9159, in adults with stable or mild-to-moderate asthma. It aims to see if the drug improves lung function and is safe. You may qualify if you have asthma with some airflow limitation and have not had recent severe flare-ups.
Nanchang, JiangxiAges 18–75 - NCT07326215Recruiting
A study of a device that removes carbon dioxide from the blood
This trial tests a device called PrismaLung+ that helps remove extra carbon dioxide from the blood of patients on breathing machines. It may help people whose lungs are struggling despite gentle ventilation settings.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07326995RecruitingPhase 2
Inhaled PA9159 for Adults with Moderate Asthma
This trial tests a new inhaled medicine called PA9159 for adults with moderate asthma. It compares the medicine to a placebo to see if it safely improves breathing and controls asthma symptoms.
Nanchang, JiangxiAges 18–75 - NCT07327359RecruitingPhase 1/Phase 2
Study of OLX72021 for male pattern baldness
This trial tests an investigational drug called OLX72021 for male pattern hair loss (androgenetic alopecia). It aims to see if the drug is safe and effective in healthy men with mild to moderate hair loss.
Camberwell, VictoriaAges 18–59 - NCT07330934RecruitingPhase 2
Study of IBI356 for moderate to severe eczema
This study tests a new medication called IBI356 for people with moderate to severe eczema that hasn't improved with standard creams. The goal is to see if this medicine can safely reduce the redness, itching, and rash.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07335211RecruitingPhase 3
Testing a new eye drop for glaucoma or high eye pressure
This trial tests a new medicine called HUC3-637 for people with primary open-angle glaucoma or ocular hypertension. It aims to see if it safely lowers eye pressure.
SeoulAges 19 years+ - NCT07335731Recruiting
Safety and effectiveness of a new robot for weight-loss surgery
This trial tests a new robot-assisted device for weight-loss surgery in people with obesity. It aims to see if the device is safe and works well for metabolic conditions.
BeijingAges 18–65 - NCT07337460RecruitingPhase 2
Icaritin plus chemotherapy for high-risk liver cancer after surgery
This trial tests combining a natural compound (Icaritin) with standard chemotherapy (mFOLFOX) after liver cancer surgery to lower the chance of the cancer coming back. It is for patients whose cancer had certain high-risk features, like a large tumor or cancer in blood vessels.
Yangzhou, JiangsuAges 18–75 - NCT07338175RecruitingPhase 3
Testing minocycline for brain bleeding recovery
This trial tests if the antibiotic minocycline can help people recover after a spontaneous brain bleed (intracerebral hemorrhage). It is for patients who have a moderate-sized bleed and are within 48 hours of symptoms starting.
Beijing, Beijing MunicipalityAges 18–80 - NCT07339540RecruitingEarly Phase 1
BCMA gene therapy for recurring autoimmune diseases
This early-phase trial tests a new gene therapy (BCMA LV injection) for people with autoimmune diseases like lupus, IgG4-related disease, scleroderma, myositis, or vasculitis that keep coming back or don't respond to standard treatments. The goal is to see if targeting a specific immune cell protein (BCMA) can help control the disease.
Wuhan, HubeiAges 18–65 - NCT07340463RecruitingPhase 2
Biologics vs standard therapy for lupus kidney disease
This trial tests two biologic drugs (belimumab or telitacicept) compared to a standard treatment (mycophenolate mofetil) for people with active lupus nephritis. The goal is to see if biologics work better at controlling kidney inflammation over 6 months.
Nanjing, JiangsuAges 14–65 - NCT07343635Recruiting
Anti-inflammatory therapy with yellow light for rosacea
This trial tests a combination of an anti-inflammatory gel (Hirudoid), yellow light therapy, and two oral medications (tofacitinib and doxycycline) for Chinese adults with mild to moderate rosacea that causes redness and visible blood vessels. The goal is to see if this approach reduces symptoms safely.
Yiwu, ZhejiangAges 18–70 - NCT07343791RecruitingEarly Phase 1
DC-CIK cell therapy plus three drugs for advanced colorectal cancer
This trial tests a combination of immune cells (DC-CIK) and three cancer drugs (epaloliposide, vortexil, and regorafenib) as a third-line treatment for people with advanced colorectal cancer that has spread. It aims to see if this mix is safe and helps shrink tumors or slow the cancer's growth.
Nanjing, JiangsuAges 18–75
Hear when a new Efficacy and Safety trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for efficacy and safety?
- Yes. Clin2 currently lists 2,799 recruiting efficacy and safety studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a efficacy and safety trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a efficacy and safety trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.